The EUropean trial on Reduction Of cardiac events with Perindopril in stable coronary Artery disease (EUROPA) demonstrated that the angiotensin-converting enzyme inhibitor, perindopril, compared with placebo, in patients with established coronary artery disease, reduced cardiovascular endpoints by 20% over a four-year follow-up period. Although the authors of this study claim that the risk reduction was best explained by blockade of the renin-angiotensin-aldosterone system, reference to recent meta-analyses of blood pressure (BP)-lowering trials provides compelling evidence that the benefits observed in the trial could be explained by the 5/2 mmHg BP difference between active and placebo treatments.
Sever P.ACE inhibitors in hypertension: still a shortage of evidence. JRAAS2000;1:117-8.
2.
MacMahon S., Peto R., Cutler J., Collins R., Sorlie P., Neaton J., Abbott R., Godwin J., Dyer, A., Stamler J.Blood pressure, stroke and coronary heart disease. Part 1, prolonged differences in blood pressure: prospective observational studies corrected for the regression dilution bias. Lancet1990 ; 335: 765-774
3.
Collins R., Peto R.Antihypertensive drug therapy: Effects on Stroke and Coronary Heart Disease . In: Textbook of Hypertension. UK, Blackwell Scientific Publications, 1994; 1156-64.
4.
Miall WE, Greenberg G.Mild hypertension: is there pressure to treat? An account of the MRC trial . Cambridge: Cambridge University Press. 1987;78-152.
5.
Grimm RH, Leon AS, Hunninghake DB, Lenz K., Hannan P., Blackburn H.Effects of thiazide diuretics on plasma lipids and lipoproteins in mildly hypertensive patients. Ann Intern Med1981 :94:7-11.
6.
Staessen, JA , Fagard R., Thijs L. et al. for the Systolic Hypertension in Europe (Syst-Eur) Trial Investigators.Randomised double-blind comparison of placebo and active treatment for older patients with isolated systolic hypertension. Lancet1997; 350: 757-64.
7.
Nayler WGReview of preclinical data of calcium channel blockers and atherosclerosis . J Cardiovasc Pharmacol1999; 33(suppl 2):S7-S11.
Hansson L., Lindholm LH, Niskanen L. et al. for the Captopril Prevention Project (CAPPP) study group.Effect of angiotensin-converting-enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: the Captopril Prevention Project (CAPPP) randomised trial . Lancet1999;353:611-16.
10.
Hansson L., Lindholm LH, Ekborn T. et al., for the STOP-2 Hypertension Study Group.Randomised trial of old and new antihypertensive drugs in elderly patients: cardiovascular mortality and morbidity. The Swedish Trial in Old Patients with Hypertension-2 study. Lancet1999;354:1751-6.
11.
Brown MJ, Palmer CR, Castaigne A., de Leeuw PW, Mancia G., Rosenthal T., Ruilope LMMorbidity and mortality in patients randomised to double-blind treatment with a long-actingcalcium channel blocker or diuretic in the International Nifedipine GITS study: Intervention as a Goal in Hypertension Treatment (INSIGHT) . Lancet2000;356:366-72.
12.
Hansson L., Hedner T., Lund-Johansen P. et al. Randomised trial of the effects of calcium antagonists compared with diuretics and ß-blockers on cardiovascular morbidity and mortality in hypertension on the Nordic Diltiazem study NORDIL. Lancet2000;356:359-65.
13.
ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group.The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA2002: 23: 2981-97
14.
Blood Pressure LoweringTreatmentTrialists' Collaboration. Effects of different blood-pressure-lowering regimens on major cardiovascular events: results of prospectively-designed overviews of randomised trials. Lancet2003;362:1527-35.
15.
EURopean trial On reduction of cardiac events with Perindopril in stable coronary Artery disease Investigators.Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomised, double-blind, placebo-controlled, multicentre trial (the EUROPA study). Lancet2003;362:782-8.
16.
The Heart Outcomes Prevention Evaluation Study Investigators.Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. New Engl JMed2000;342: 145-53.
17.
Williams B.The renin angiotensin system and cardiovascular disease: hope or hype?JRAAS2000; 1:142-6.
18.
Svenson P., de Faire U., Sleight P., Yusuf S., Ostergren J.Comparative effects of ramipril on ambulatory and office blood pressures; a HOPE Substudy. Hypertension2001;38: e28.
19.
White HDShould all patients with coronary disease receive angiotensin-converting-enzyme inhibitors? Commentary. Lancet2003;362:755-7.
20.
Mann J., Julius S.The Valsartan Antihypertensive Long-term Use Evaluation (VALUE) trial of cardiovascular events in hypertension. Rationale and design. Blood Press1998;7:176-83.
21.
Sever P., Dahlof B., Poulter N. et al., for the ASCOT Investigators.Rationale, design, methods and baseline demography of participants of the Anglo-Scandinavian Cardiac Outcomes Trial. J Hypertens2001;19:1139-47.
